Tue, March 18, 2025
Mon, March 17, 2025
Sun, March 16, 2025
[ Sun, Mar 16th ]: techUK
techUK Scale-Up Action Plan
Sat, March 15, 2025
Fri, March 14, 2025
[ Fri, Mar 14th ]: TheStreet
Tax trends and myths
Thu, March 13, 2025
Wed, March 12, 2025

Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal


  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. -agree-to-merge-in-6-7b-cash-and-stock-deal.html
  Print publication without navigation Published in Business and Finance on by Dealbreaker

When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a yet-to-be-determined name and is expected to trade on the New

Mallinckrodt and Endo International have agreed to merge in a deal valued at $6.7 billion, combining their operations in a strategic move to enhance their market position in the pharmaceutical industry. The merger, which includes both cash and stock, aims to create a more robust entity capable of tackling the challenges of the pharmaceutical market, including regulatory pressures and competition. This consolidation is expected to streamline operations, reduce costs, and potentially accelerate the development and distribution of new treatments. The agreement comes at a time when both companies are facing various legal and financial issues, including Mallinckrodt's ongoing bankruptcy proceedings and Endo's efforts to manage its debt. The merger is subject to approval by shareholders and regulatory bodies.

Read the Full Dealbreaker Article at:
[ https://www.msn.com/en-us/money/companies/pharma-firms-mallinckrodt-and-endo-agree-to-merge-in-6-7b-cash-and-stock-deal/ar-AA1AWwnt ]

Publication Contributing Sources